Molecular Analysis for Therapy Choice (MATCH)

K
Kathy Miller, MD

Primary Investigator

Overview

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Description

The purpose of this study is to evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma,Glioma, Head and Neck Carcinoma, Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Ovarian Carcinoma, Pancreatic Carcinoma, Plasma Cell Myeloma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Plasma Cell Myeloma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Women of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration
Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
Patients must have measurable disease
Patients must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy for molecular profiling; biopsy must not be considered to be more than minimal risk to the patient
Patient must not require the use of full dose coumarin-derivative anticoagulants such as warfarin; low molecular weight heparin is permitted for prophylactic or therapeutic use; stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status == 4 weeks prior to registration to Step 0
Patients must have discontinued steroids >= 1 week prior to registration to Step 0; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to Step 0
Exclusion Criteria
Patients that are pregnant or breast feeding are excluded


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1506163289 (EAY131/MATCH)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center